Immunotherapy as Second-line in Patient With Small Cell Lung Cancer
NCT ID: NCT03059667
Last Updated: 2021-02-10
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE2
Total Enrollment
73 participants
Study Classification
INTERVENTIONAL
Study Start Date
2017-03-13
Study Completion Date
2020-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Chemotherapy still constitutes the backbone of small-cell lung cancer (SCLC) therapy, particularly in the extensive disease (ED) stage (ED-SCLC). Despite the fact that a substantial complete response rate could be achieved in SCLC patients receiving etoposide - cisplatin doublet, cure remains the exception. Overall survival in patients receiving this combination is 10 months and progression free survival 6.3 months. At time of progression two options are hitherto accepted: reinduction of carboplatin - etoposide doublet or, for patients unfit for reinduction, topotecan single-drug regimen. However, in both clinical cases, median survival hardly achieves 33 weeks. Consistent data using anti - PDL1 (Programmed death-ligand 1) or anti PD1 (programmed cell death 1) antibodies suggest that they are active as single drug regimens in many malignant diseases. Taking into account the rich tumor infiltrating lymphocyte in pathological specimens of SCLC, we can hypothesize that experimental use of ATEZOLIZUMAB (MPDL3280A) in patients is ethical pending that it demonstrates activity in the second line setting.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Combined Atezolizumab and Chemotherapy (Carboplatin Plus Etoposide) in Neoadjuvant Treating Limited-Stage Small Cell Lung Cancer Patients
NCT04696939
Small-cell Lung Cancer
Neoadjuvant Therapy
UNKNOWN
PHASE2
A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy
NCT03191786
Non-Small Cell Lung Cancer
COMPLETED
PHASE3
A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)
NCT02763579
Small Cell Lung Carcinoma
COMPLETED
PHASE3
A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)
NCT03456063
Non-Small-Cell Lung
ACTIVE_NOT_RECRUITING
PHASE3
A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT02367781
Carcinoma, Non-Squamous Non-Small Cell Lung
COMPLETED
PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Small Cell Lung Cancer
Small Cell Lung Cancer Limited Stage
Small Cell Lung Cancer Extensive Stage
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm A : chemotherapy
Patients randomly assigned to the control arm will receive either:
* topotecan (oral 2.3 mg/m² or IV 1.5 mg/m² day 1-4 recommended)
* or re-induction by carboplatin - etoposide chemotherapy.
Group Type
ACTIVE_COMPARATOR
Topotecan
Intervention Type
DRUG
oral 2.3 mg/m² or IV 1.5 mg/m² day 1-4 recommended
Carboplatin
Intervention Type
DRUG
In accordance with the summary of product characteristics.
Etoposide
Intervention Type
DRUG
In accordance with the summary of product characteristics.
Arm B : immune therapy
Patients randomly assigned to the experimental arm will receive Anti PDL1 ATEZOLIZUMAB (MPDL3280A) at a fixed dose of 1200 mg IV every three weeks until progression or unacceptable toxicity.
Group Type
EXPERIMENTAL
Atezolizumab
Intervention Type
DRUG
Atezolizumab at 1200 mg IV every 3 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Atezolizumab
Atezolizumab at 1200 mg IV every 3 weeks
Intervention Type
DRUG
Topotecan
oral 2.3 mg/m² or IV 1.5 mg/m² day 1-4 recommended
Intervention Type
DRUG
Carboplatin
In accordance with the summary of product characteristics.
Intervention Type
DRUG
Etoposide
In accordance with the summary of product characteristics.
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Histologically confirmed small-cell lung cancer.
2. Extensive or limited disease according to the criteria of the Veteran's Administration Lung Cancer Group: (disease extended is defined as a disease beyond hemi thorax and supraclavicular lymph node areas. Tumor pleural effusion will be considered as extended disease).
3. Targetable tumor lesions according to RECIST 1.1. Tumor involvement encompassed into a radiotherapy field is eligible as target pending that progression is documented.
4. Tumor sample sent to IFCT for PD-L1 immunohistochemistry
5. Previous platinum - etoposide treatment for at least 2 cycles.
6. Demonstrated progression of the disease other than brain metastasis or carcinomatous meningitis.
For the patient relapsing more than one year after the end of the previous treatment, a new histological confirmation is required before randomization.
7. Age over 18 years.
8. Weight loss ≤ 10% during the last three months.
9. Patients with brain metastases at diagnosis will be eligible pending that they have achieved brain response during the first line therapy (including brain radiotherapy is required) and remain in brain tumor response during the two months prior to randomization.
10. Performance Status 0-2
11. Creatinine clearance \> 40 mL/min.
12. Neutrophils ≥ 2,000 µL-1 and platelets ≥ 100,000 µL-1.
13. Bilirubin ≤ 1.5 x normal.
14. Transaminases, alkaline phosphatases ≤ 2.5 x ULN except in case of liver metastases (5 x ULN).
15. Electrocardiogram without sign of progressive coronaropathy.
16. No approved or investigational anti-cancer therapy concurrently or in the 5 years prior to start of study drug except the first line of treatment of the SCLC, including tumor embolization, chemotherapy, radiation therapy, immunotherapy, hormone therapy, biologic therapy, or anti angiogenic therapy (e.g., inhibitors of VEGF or VEGFR (Vascular Endothelial Growth Factor Receptor).
17. Signed informed consent
18. A female is eligible to enter and participate in this study if she is of:
Non-childbearing potential (i.e., physiologically incapable of becoming pregnant), including any female who has undergone:
* Hysterectomy.
* Bilateral oophorectomy (ovariectomy).
* Bilateral tubal ligation.
* Or who is post-menopausal:
* Patients not using hormone replacement therapy (HRT) must have experienced total cessation of menses for ≥1 year and be greater than 45 years in age, OR, in questionable cases, have a follicle stimulating hormone value \>40 mIU/mL and an estradiol value \<40 pg/mL (\<140 pmol/L).
* Subject using HRT must have experienced total cessation of menses for ≥ 1 year and be greater than 45 years of age OR have had documented evidence of menopause based on FSH (Follicle Stimulating Hormone) and estradiol concentrations prior to initiation of HRT (Hormone Replacement Therapy).
Childbearing potential, including any female who has had a negative serum pregnancy test within 1 week prior to the first dose of study treatment, preferably as close to the first dose as possible, and agrees to use adequate contraception. Contraceptive methods acceptable to the IFCT, when used consistently and in accordance with both the product label and the instructions of the physician, are as follow:
* An intrauterine device with a documented failure rate of less than 1% per year.
* Male partner sterilization (vasectomy with documentation of azoospermia) prior to the female subject's entry and is the sole sexual partner for that female.
* Complete abstinence from sexual intercourse for 14 days before exposure to investigational product, through the dosing period, and for at least 21 days after the last dose of investigational product.
* Double-barrier contraception: condom and an occlusive cap (diaphragm or cervical/vault caps) with a vaginal spermicidal agent (foam/gel/film/cream/suppository)
* Oral contraceptive, either combined or progestogen alone
* Injectable progestogen
* Implant of levonorgestrel
* Estrogenic vaginal ring
* Percutaneous contraceptive patches The contraceptive methods must be used during all the time of the treatment and must be maintained during 5 months after the end of the treatment in the Atezolizumab arm and 30 days for women, 90 days for men, after the end of the treatment in the chemotherapy arm.
Female patients who are lactating should discontinue nursing prior to the first dose of study drug and should refrain from nursing throughout the treatment period and for 15 days following the last dose of study drug.
A male with a female partner of childbearing potential is eligible to enter and participate in the study if he uses a barrier method of contraception or abstinence during the study.
2. Extensive or limited disease according to the criteria of the Veteran's Administration Lung Cancer Group: (disease extended is defined as a disease beyond hemi thorax and supraclavicular lymph node areas. Tumor pleural effusion will be considered as extended disease).
3. Targetable tumor lesions according to RECIST 1.1. Tumor involvement encompassed into a radiotherapy field is eligible as target pending that progression is documented.
4. Tumor sample sent to IFCT for PD-L1 immunohistochemistry
5. Previous platinum - etoposide treatment for at least 2 cycles.
6. Demonstrated progression of the disease other than brain metastasis or carcinomatous meningitis.
For the patient relapsing more than one year after the end of the previous treatment, a new histological confirmation is required before randomization.
7. Age over 18 years.
8. Weight loss ≤ 10% during the last three months.
9. Patients with brain metastases at diagnosis will be eligible pending that they have achieved brain response during the first line therapy (including brain radiotherapy is required) and remain in brain tumor response during the two months prior to randomization.
10. Performance Status 0-2
11. Creatinine clearance \> 40 mL/min.
12. Neutrophils ≥ 2,000 µL-1 and platelets ≥ 100,000 µL-1.
13. Bilirubin ≤ 1.5 x normal.
14. Transaminases, alkaline phosphatases ≤ 2.5 x ULN except in case of liver metastases (5 x ULN).
15. Electrocardiogram without sign of progressive coronaropathy.
16. No approved or investigational anti-cancer therapy concurrently or in the 5 years prior to start of study drug except the first line of treatment of the SCLC, including tumor embolization, chemotherapy, radiation therapy, immunotherapy, hormone therapy, biologic therapy, or anti angiogenic therapy (e.g., inhibitors of VEGF or VEGFR (Vascular Endothelial Growth Factor Receptor).
17. Signed informed consent
18. A female is eligible to enter and participate in this study if she is of:
Non-childbearing potential (i.e., physiologically incapable of becoming pregnant), including any female who has undergone:
* Hysterectomy.
* Bilateral oophorectomy (ovariectomy).
* Bilateral tubal ligation.
* Or who is post-menopausal:
* Patients not using hormone replacement therapy (HRT) must have experienced total cessation of menses for ≥1 year and be greater than 45 years in age, OR, in questionable cases, have a follicle stimulating hormone value \>40 mIU/mL and an estradiol value \<40 pg/mL (\<140 pmol/L).
* Subject using HRT must have experienced total cessation of menses for ≥ 1 year and be greater than 45 years of age OR have had documented evidence of menopause based on FSH (Follicle Stimulating Hormone) and estradiol concentrations prior to initiation of HRT (Hormone Replacement Therapy).
Childbearing potential, including any female who has had a negative serum pregnancy test within 1 week prior to the first dose of study treatment, preferably as close to the first dose as possible, and agrees to use adequate contraception. Contraceptive methods acceptable to the IFCT, when used consistently and in accordance with both the product label and the instructions of the physician, are as follow:
* An intrauterine device with a documented failure rate of less than 1% per year.
* Male partner sterilization (vasectomy with documentation of azoospermia) prior to the female subject's entry and is the sole sexual partner for that female.
* Complete abstinence from sexual intercourse for 14 days before exposure to investigational product, through the dosing period, and for at least 21 days after the last dose of investigational product.
* Double-barrier contraception: condom and an occlusive cap (diaphragm or cervical/vault caps) with a vaginal spermicidal agent (foam/gel/film/cream/suppository)
* Oral contraceptive, either combined or progestogen alone
* Injectable progestogen
* Implant of levonorgestrel
* Estrogenic vaginal ring
* Percutaneous contraceptive patches The contraceptive methods must be used during all the time of the treatment and must be maintained during 5 months after the end of the treatment in the Atezolizumab arm and 30 days for women, 90 days for men, after the end of the treatment in the chemotherapy arm.
Female patients who are lactating should discontinue nursing prior to the first dose of study drug and should refrain from nursing throughout the treatment period and for 15 days following the last dose of study drug.
A male with a female partner of childbearing potential is eligible to enter and participate in the study if he uses a barrier method of contraception or abstinence during the study.
Exclusion Criteria
1. Non-small cell lung cancer or mixed small-cell lung cancer - non small cell cancer.
2. Prior immunotherapy
3. Last dose of the previous treatment received less than 21 days before randomization (washout period).
4. Corticosteroid with a daily dose over 10 mg prednisolone or equivalent for more than 10 days during the previous month.
5. Unstable angina or uncontrolled cardiac disease.
6. Progressive infection (suggested by a fever associated with hyperleukocytosis, increase procalcitonin, and increase of C reactive protein without link with a paraneoplastic syndrome).
7. Patient not able to follow the therapeutic program.
8. Natremia \< 125 mmol/L except in case of corrective treatment before the beginning of the therapy.
9. Hypercalcemia despite corrective treatment (corrected calcemia = Ca++ (mmol) + \[(40-alb (g)) x 0.025\].
10. Psychic or mental disease that do not allow the patient to give informed consent.
11. Pregnant or lactating female.
12. Systemic immunosuppressive therapy (eg cyclophosphamide, azathioprine, methotrexate, thalidomide and anti-tumor necrosis factor \[TNF\]) during the two weeks preceding the day 1 of cycle 1.
13. Auto-immune disease. History of autoimmune disease, including myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with anti-phospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, syndrome Guillain-Barré, multiple sclerosis, vasculitis or glomerulonephritis. Patients with a history of hypothyroidism origin autoimmune treated with a stable dose replacement therapy may be eligible for this study. Patients with controlled type 1 diabetes treated with insulin are eligible in this study.
14. Idiopathic pulmonary fibrosis history, organizing pneumonia (eg, bronchiolitis obliterans), drug-induced lung disease, idiopathic pulmonary or active signs of pneumonia or interstitial lung infiltrate (any cause) detected on the lung scan selection
15. Prior malignancy. Note: Patients who have had another malignancy and were treated more than 5 years ago and have since been considered cured, or patients with a history of basocellular skin carcinoma or in situ carcinoma of the uterine cervix are eligible.
16. Presence of any concurrent disease or condition that would make the subject inappropriate for study participation including any unresolved or unstable, serious toxicity from prior administration of another investigational drug or any serious medical disorder that would interfere with the subject's safety, obtaining informed consent, or compliance with all study related procedures.
17. Administration of a live attenuated vaccine during the four weeks preceding the day 1 of cycle 1, or administration of a vaccine of this type scheduled during the study. An influenza vaccine should be administered during the influenza season (approximately from October to March). Patients should not receive a live attenuated influenza vaccine during the four weeks preceding the day 1 of cycle 1, and shall not receive a vaccine of this type during the study.
18. History of human immunodeficiency virus infection or chronic hepatitis B or C.
19. Presence of active or uncontrolled infection.
20. Psoriasis patients
21. History of any one or more of the following cardiovascular conditions within the past 6 months:
* Coronary/peripheral artery bypass graft, cardiac angioplasty or stenting.
* Myocardial infarction.
* Severe/unstable angina pectoris.
* Symptomatic peripheral vascular disease, pulmonary embolism or untreated deep venous thrombosis (DVT), cerebrovascular accident or transient ischemic attack.
* Note: Subject with recent DVT who have been treated with therapeutic anti-coagulating agents for at least 6 weeks are eligible
* Class III or IV congestive heart failure, as defined by the New York Heart Association.
22. Concurrent treatment with an investigational agent or participation in another clinical trial.
2. Prior immunotherapy
3. Last dose of the previous treatment received less than 21 days before randomization (washout period).
4. Corticosteroid with a daily dose over 10 mg prednisolone or equivalent for more than 10 days during the previous month.
5. Unstable angina or uncontrolled cardiac disease.
6. Progressive infection (suggested by a fever associated with hyperleukocytosis, increase procalcitonin, and increase of C reactive protein without link with a paraneoplastic syndrome).
7. Patient not able to follow the therapeutic program.
8. Natremia \< 125 mmol/L except in case of corrective treatment before the beginning of the therapy.
9. Hypercalcemia despite corrective treatment (corrected calcemia = Ca++ (mmol) + \[(40-alb (g)) x 0.025\].
10. Psychic or mental disease that do not allow the patient to give informed consent.
11. Pregnant or lactating female.
12. Systemic immunosuppressive therapy (eg cyclophosphamide, azathioprine, methotrexate, thalidomide and anti-tumor necrosis factor \[TNF\]) during the two weeks preceding the day 1 of cycle 1.
13. Auto-immune disease. History of autoimmune disease, including myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with anti-phospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, syndrome Guillain-Barré, multiple sclerosis, vasculitis or glomerulonephritis. Patients with a history of hypothyroidism origin autoimmune treated with a stable dose replacement therapy may be eligible for this study. Patients with controlled type 1 diabetes treated with insulin are eligible in this study.
14. Idiopathic pulmonary fibrosis history, organizing pneumonia (eg, bronchiolitis obliterans), drug-induced lung disease, idiopathic pulmonary or active signs of pneumonia or interstitial lung infiltrate (any cause) detected on the lung scan selection
15. Prior malignancy. Note: Patients who have had another malignancy and were treated more than 5 years ago and have since been considered cured, or patients with a history of basocellular skin carcinoma or in situ carcinoma of the uterine cervix are eligible.
16. Presence of any concurrent disease or condition that would make the subject inappropriate for study participation including any unresolved or unstable, serious toxicity from prior administration of another investigational drug or any serious medical disorder that would interfere with the subject's safety, obtaining informed consent, or compliance with all study related procedures.
17. Administration of a live attenuated vaccine during the four weeks preceding the day 1 of cycle 1, or administration of a vaccine of this type scheduled during the study. An influenza vaccine should be administered during the influenza season (approximately from October to March). Patients should not receive a live attenuated influenza vaccine during the four weeks preceding the day 1 of cycle 1, and shall not receive a vaccine of this type during the study.
18. History of human immunodeficiency virus infection or chronic hepatitis B or C.
19. Presence of active or uncontrolled infection.
20. Psoriasis patients
21. History of any one or more of the following cardiovascular conditions within the past 6 months:
* Coronary/peripheral artery bypass graft, cardiac angioplasty or stenting.
* Myocardial infarction.
* Severe/unstable angina pectoris.
* Symptomatic peripheral vascular disease, pulmonary embolism or untreated deep venous thrombosis (DVT), cerebrovascular accident or transient ischemic attack.
* Note: Subject with recent DVT who have been treated with therapeutic anti-coagulating agents for at least 6 weeks are eligible
* Class III or IV congestive heart failure, as defined by the New York Heart Association.
22. Concurrent treatment with an investigational agent or participation in another clinical trial.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Intergroupe Francophone de Cancerologie Thoracique
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jean-Louis PUJOL, MD PhD
Role: PRINCIPAL_INVESTIGATOR
CHU de Montpellier
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Annemasse - CH
Ambilly, , France
Site Status
Angers - CHU
Angers, , France
Site Status
CH
Colmar, , France
Site Status
CHRU Grenoble
Grenoble, , France
Site Status
Centre Hospitalier - Pneumologie
Le Mans, , France
Site Status
Lorient - CHBS
Lorient, , France
Site Status
Montpellier - CHRU
Montpellier, , France
Site Status
Mulhouse - CH
Mulhouse, , France
Site Status
Centre Antoine Lacassagne
Nice, , France
Site Status
AP-HP Hopital Tenon - Pneumologie
Paris, , France
Site Status
APHP - Paris Bichat
Paris, , France
Site Status
GH Paris Saint-Joseph
Paris, , France
Site Status
CHG de Pau
Pau, , France
Site Status
HCL - Lyon Sud (Pneumologie)
Pierre-Bénite, , France
Site Status
Rouen - CHU
Rouen, , France
Site Status
Centre Hospitalier
Saint-Quentin, , France
Site Status
Toulouse - CHU Larrey
Toulouse, , France
Site Status
CHU Tours - Pneumologie
Tours, , France
Site Status
Countries
Review the countries where the study has at least one active or historical site.
France
References
Explore related publications, articles, or registry entries linked to this study.
Negre E, Coffy A, Langlais A, Daures JP, Lavole A, Quoix E, Molinier O, Greillier L, Audigier-Valette C, Moro-Sibilot D, Westeel V, Morin F, Roch B, Pujol JL. Development and Validation of a Simplified Prognostic Score in SCLC. JTO Clin Res Rep. 2020 Feb 12;1(1):100016. doi: 10.1016/j.jtocrr.2020.100016. eCollection 2020 Mar.
Reference Type
DERIVED
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IFCT-1603
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]
NCT02367794
COMPLETED
PHASE3
Durvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease Small-sell Lung Cancer (SCLC)
NCT05856695
ACTIVE_NOT_RECRUITING
PHASE2
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
NCT02486718
ACTIVE_NOT_RECRUITING
PHASE3
A Study on the Efficacy of Atezolizumab Combined with Chemotherapy
NCT06780826
RECRUITING
Atezolizumab as Induction Therapy in Non-small Cell Lung Cancer
NCT02994576
COMPLETED
PHASE2
A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy
NCT02008227
COMPLETED
PHASE3
A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With the Therapeutic Vaccine Named TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC)
NCT03353675
COMPLETED
PHASE2
Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung Cancer
NCT04622228
COMPLETED
PHASE2
Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer
NCT02963090
TERMINATED
PHASE2
Study to Assess Safety,Tolerability,Efficacy of PM01183 and Atezolizumab in Patients w/ Advanced Small Cell Lung Cancer.
NCT04253145
RECRUITING
PHASE1/PHASE2
Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC)
NCT03663166
TERMINATED
PHASE1/PHASE2
A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing Chemotherapy
NCT02813785
COMPLETED
PHASE3
An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy
NCT02538666
COMPLETED
PHASE3
A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)
NCT02657434
COMPLETED
PHASE3
Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy
NCT03977194
ACTIVE_NOT_RECRUITING
PHASE3
Atezolizumab After Concurrent Chemo-radiotherapy Versus Chemo-radiotherapy Alone in Limited Disease Small-cell Lung Cancer
NCT03540420
ACTIVE_NOT_RECRUITING
PHASE2
Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).
NCT06663098
RECRUITING
PHASE2
A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3)
NCT02927301
COMPLETED
PHASE2
A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)
NCT03066778
COMPLETED
PHASE3
Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide
NCT04221529
COMPLETED
PHASE2
SCLC on the 2nd Line With Relapsed After Response to Chemotherapy GFPC 01-2013
NCT02738346
UNKNOWN
PHASE3
A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]
NCT02409342
COMPLETED
PHASE3
Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy
NCT04691817
RECRUITING
PHASE1/PHASE2
A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC
NCT03215706
COMPLETED
PHASE3